Managed virological reaction after treatment with daclatasvir/pegylated interferon and ribavirin as a component of a clinical trial in a cirrhotic human immunodeficiency infection
Keywords:
Human immunodeficiency virus (HIV), hepatitis C, daclatasvir, liver decompensation, sustained virological response, HIV/hepatitis C co-infection.Abstract
This study presents a case of a sustained virological response to 24 weeks early cessation of hepatitis C
direct acting antiviral (DAA) treatment with daclatasvir/peginterferon (PEG-IFN)/ribavirin (RBV), mandated
by liver decompensation, in a clinical trial subject with advanced liver disease and human
immunodeficiency virus (HIV)/hepatitis C virus (HCV) co-infection.
Downloads
Published
2015-04-19
Issue
Section
Articles
How to Cite
Managed virological reaction after treatment with daclatasvir/pegylated interferon and ribavirin as a component of a clinical trial in a cirrhotic human immunodeficiency infection . (2015). African Journal of AIDS and HIV Research , 3(1), 23-25. https://kevinpage.org/index.php/AJAHR/article/view/700
